• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Well-known drug has less risk for preterm delivery in PCOS

Bioengineer by Bioengineer
April 1, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Metformin can halve the risk of late miscarriage and preterm births for women with polycystic ovary syndrome (PCOS).

PCOS occurs in 10 to 15 per cent of all women. The symptoms are irregular menstrual periods, increased levels of male sex hormones and small ovarian blisters. In addition, many women with PCOS are overweight. Women with PCOS also have an increased incidence of impaired fertility, miscarriages, gestational diabetes, premature births and pre-eclampsia.

“In pregnant women with PCOS, treatment with metformin from the end of the first trimester may reduce the risk of late miscarriages and preterm births,” states Professor Eszter Vanky.

Professor Vanky leads the research group “Women’s Health – PCOS” at the Norwegian University of Science and Technology (NTNU)’s Department of Clinical and Molecular Medicine.

A new article appearing in the Lancet Diabetes & Endocrinology journal presents the results of nearly two decades of research from NTNU and St. Olavs Hospital. Consultant Tone S. Løvvik is the first author, and the study is part of her doctoral work. Professor Sven M. Carlsen is co-supervisor.

However, the research group surprisingly found no reduction of gestational diabetes among this cohort of women with PCOS.

From 2000 to 2017, the research group carried out three controlled studies of nearly 800 pregnant women with PCOS. The studies were conducted at 15 hospitals in Norway, 4 hospitals in Sweden and one in Iceland. Half of the women were given metformin (2000 milligrams daily) from first trimester to delivery. The rest of the women were given a placebo.

In addition to a lower risk of late miscarriage and preterm births, the researchers also found that the women who received metformin gained less weight during pregnancy.

A higher level of male sex hormones is associated with several of the symptoms of PCOS. The causes of the condition are not known, but may be related to lifestyle, inheritance and intrauterine fetal life.

The group found no effect on pre-eclampsia, pregnancy-induced high blood pressure or to what extent newborns of women with PCOS needed intensive care.

“Perhaps the most remarkable finding was that metformin had no effect whatsoever on either the incidence or severity of gestational diabetes,” Vanky notes.

Metformin is a well-known drug used in the treatment of type 2 diabetes, and in some countries regarded as equivalent to insulin as a first-line drug therapy for gestational diabetes.

The three studies that form the basis of the conclusion were carried out according to Good Clinical Practice principles and will have an impact on the follow-up and treatment of pregnant women with PCOS and likely also of other pregnant women.

Another part of the study followed up children of mothers with PCOS who used metformin, and a control group that was given a placebo. The result of this survey were recently published by The Lancet Child and Adolescent Health

###

The work was financed by the Research Council of Norway, St. Olavs Hospital, NTNU and Novo Nordisk.

Source: Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial

Tone S Løvvik, PhD, Prof Sven M Carlsen, MD, Øyvind Salvesen, PhD, Berglind Steffensen, MD, Prof Marie Bixo, MD, Prof Francisco Gómez-Real, PhD et al. DOI: https://doi.org/10.1016/S2213-8587(19)30002-6 https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30002-6/fulltext

Media Contact
Eszter Vanky
[email protected]

Related Journal Article

https://geminiresearchnews.com/2019/03/well-known-drug-has-less-risk-for-preterm-delivery-in-pcos/
http://dx.doi.org/10.1016/S2213-8587(19)30002-6

Tags: Clinical TrialsDiet/Body WeightEating Disorders/ObesityGynecologyMedicine/HealthPediatricsPublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Unraveling EMT’s Role in Colorectal Cancer Spread

August 2, 2025
Gut γδ T17 Cells Drive Brain Inflammation via STING

Gut γδ T17 Cells Drive Brain Inflammation via STING

August 2, 2025

Agent-Based Framework for Assessing Environmental Exposures

August 2, 2025

MARCO Drives Myeloid Suppressor Cell Differentiation, Immunity

August 2, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    38 shares
    Share 15 Tweet 10
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unraveling EMT’s Role in Colorectal Cancer Spread

Gut γδ T17 Cells Drive Brain Inflammation via STING

Agent-Based Framework for Assessing Environmental Exposures

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.